Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4548611
Max Phase: Preclinical
Molecular Formula: C50H73N10O24P
Molecular Weight: 1229.15
Molecule Type: Unknown
Associated Items:
ID: ALA4548611
Max Phase: Preclinical
Molecular Formula: C50H73N10O24P
Molecular Weight: 1229.15
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CC[C@H](C)[C@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)NC(C)=O)[C@@H](C)O)C(=O)N[C@@H](Cc1cc(=O)oc2cc(OP(=O)(O)O)ccc12)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(N)=O)C(C)C
Standard InChI: InChI=1S/C50H73N10O24P/c1-9-22(6)40(59-50(79)41(23(7)62)60-47(76)33(19-61)57-45(74)31(17-36(66)67)52-24(8)63)49(78)56-30(13-25-14-38(70)83-34-15-26(10-11-27(25)34)84-85(80,81)82)44(73)54-32(18-37(68)69)46(75)58-39(21(4)5)48(77)55-29(12-20(2)3)43(72)53-28(42(51)71)16-35(64)65/h10-11,14-15,20-23,28-33,39-41,61-62H,9,12-13,16-19H2,1-8H3,(H2,51,71)(H,52,63)(H,53,72)(H,54,73)(H,55,77)(H,56,78)(H,57,74)(H,58,75)(H,59,79)(H,60,76)(H,64,65)(H,66,67)(H,68,69)(H2,80,81,82)/t22-,23+,28-,29-,30-,31-,32-,33-,39-,40-,41-/m0/s1
Standard InChI Key: WGKSNFBRKMUBQT-AUYKUYRXSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1229.15 | Molecular Weight (Monoisotopic): 1228.4537 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Ma ES, Barrios AM.. (2019) Rational design of a SHP-2 targeted, fluorogenic peptide substrate., 29 (17): [PMID:31351693] [10.1016/j.bmcl.2019.07.034] |
Source(1):